Enabling highly automated screening solution for latent tuberculosis in all throughput segments Embedding QuantiFERON assays in the broad assay menu of DiaSorin’s LIAISON analyzers also gives current ...
HILDEN, Germany & SALUGGIA, Italy--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE Italy Mid Cap: DIA) today announced the introduction of an automated, ...
Venlo, the Netherlands, June 15, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) welcomes the publication of a new, systematic review highlighting the unique value of its ...
Jan. 11, 2005 — The U.S. Food and Drug Administration (FDA) has approved a test to identify individual patient variations in drug metabolism; an implant system that simplifies the arthroscopic ...
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the Health Canada regulatory approval of QuantiFERON®-TB Gold Plus ...
Clinical Infectious Diseases publishes clinically relevant articles on the pathogenesis, clinical investigation, medical microbiology, diagnosis, immune mechanisms, and treatment of diseases caused by ...
Qiagen ($QGEN) pointed to a head-to-head comparison study in The Lancet showing that its Quantiferon-TB Gold tuberculosis test could be more accurate at detecting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results